New antibody drug aims to halt Scleroderma's damage
Disease control
Recruiting now
This Phase 2 trial tests a drug called tibulizumab in 80 adults with systemic sclerosis, a disease that causes skin thickening and can damage organs. Participants first receive either the drug or a placebo for 24 weeks, then everyone who continues gets the drug for another 28 wee…
Phase: PHASE2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC